Pratyria

Package leaflet: Information for the user

Pratyria, 75 mg, prolonged-release injection suspension in pre-filled syringe
Pratyria, 100 mg, prolonged-release injection suspension in pre-filled syringe
Pratyria, 150 mg, prolonged-release injection suspension in pre-filled syringe
Initiation pack
Pratyria, 150 mg, prolonged-release injection suspension in pre-filled syringe
Pratyria, 100 mg, prolonged-release injection suspension in pre-filled syringe
Paliperidone
Please read all of this leaflet carefully before using this medicine, because it contains
important information for the patient.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, please ask your doctor, pharmacist, or nurse.
• If you experience any side effects, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. See section 4.

Leaflet contents

1. What Pratyria is and what it is used for
2. What you need to know before using Pratyria
3. How to use Pratyria
4. Possible side effects
5. How to store Pratyria
6. Contents of the pack and other information

1. What Pratyria is and what it is used for

Pratyria contains the active substance paliperidone, which belongs to a group of medicines called antipsychotics.
It is used for the maintenance treatment of symptoms of schizophrenia in adult patients who are already stabilized on paliperidone or risperidone.
For patients who previously responded to oral paliperidone or risperidone and whose psychotic symptoms are mild to moderate, your doctor may initiate treatment with Pratyria without prior stabilization with paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive symptoms mean the presence of symptoms that usually do not occur. For example, a person with schizophrenia may hear voices or see things that are not there (hallucinations), believe in things that are not true (delusions), or be excessively suspicious of others. Negative symptoms mean the absence of usual behaviors or emotions. For example, a person with schizophrenia may appear withdrawn, isolated, emotionally unresponsive, or may have difficulty speaking clearly and logically. People affected by this disorder may also experience depression, anxiety, feelings of guilt, or tension.
Pratyria helps to reduce the symptoms of the illness and prevent their recurrence.

2. Important information before using Pratyria

When NOT to use Pratyria

• If the patient is allergic to paliperidone or any of the other ingredients of this medicine (listed in section 6).
• If the patient is allergic to another antipsychotic medicine, including the substance risperidone.

Warnings and precautions
Before starting treatment with Pratyria, discuss this with your doctor, pharmacist, or nurse.
The use of this medicine in elderly patients with dementia has not been studied. However, in such patients treated with other similar medicines, an increased risk of stroke or death may occur (see section 4, Possible side effects).
All medicines have side effects, and some of the side effects of this medicine may worsen symptoms of other medical conditions. For this reason, during treatment with this medicine, discuss with your doctor if any of the following conditions apply:

• if the patient has Parkinson's disease
• if the patient has ever been diagnosed with a condition characterized by high fever and muscle stiffness (also known as neuroleptic malignant syndrome)
• if the patient has ever experienced abnormal movements of the tongue or facial muscles (tardive dyskinesia)
• if the patient has previously had a low white blood cell count (whether or not caused by other medicines)
• if the patient has diabetes or is predisposed to developing diabetes
• if the patient has breast cancer or a pituitary gland tumor
• if the patient has heart disease or is being treated for heart conditions that predispose to hypotension
• if the patient has low blood pressure upon sudden change to standing or sitting position
• if the patient has epilepsy
• if the patient has kidney function disorders
• if the patient has liver function disorders
• if the patient experiences prolonged and (or) painful erection
• if the patient has problems with body temperature regulation or overheating
• if the patient has abnormally increased levels of prolactin hormone in the blood or suspected prolactin-dependent tumor
• if the patient or their family members have had blood clots in blood vessels, as antipsychotic medicines are associated with their development.

If the patient meets any of the above criteria, they should consult their doctor, who may adjust the dose or monitor the patient periodically.

• The treating doctor may order a white blood cell count test, as very rarely, dangerously low levels of certain types of white blood cells essential for fighting infections have been observed in patients taking this medicine.
• Even if the patient previously tolerated oral paliperidone or risperidone, allergic reactions may rarely occur after Pratyria injections. Immediate medical help should be sought if the patient develops rash, throat swelling, itching, or difficulty breathing, as these may be symptoms of a severe allergic reaction.
• This medicine may cause weight gain. Significant weight gain may negatively affect the patient's health. The treating doctor will regularly monitor the patient's body weight.
• The treating doctor will check for symptoms of elevated blood sugar levels, as new-onset diabetes or worsening of pre-existing diabetes has been observed in patients taking this medicine. In patients with pre-existing diabetes, blood glucose levels should be monitored regularly.
• Since this medicine may suppress vomiting, it may mask the body's normal response to ingesting toxic substances or other medical conditions.
• During cataract removal surgery, the pupil (black circle in the center of the eye) may not dilate sufficiently. Also, the iris (colored part of the eye) may be flaccid during surgery, which may result in eye damage. If the patient has planned eye surgery, they should inform the ophthalmologist about taking this medicine.

Children and adolescents
This medicine is not used in individuals under 18 years of age.
Pratyria and other medicines
Tell your doctor about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to use.

• Taking this medicine together with carbamazepine (an antiepileptic and mood stabilizer) may require adjustment of the Pratyria dose.
• Since this medicine acts primarily in the brain, combining it with other medicines such as other psychotropic medicines, opioids, antihistamines, and sedatives that act on the brain may intensify side effects such as drowsiness or other effects on the brain.
• This medicine may lower blood pressure; therefore, caution is advised when using this medicine together with other medicines that lower blood pressure.
• This medicine may reduce the effectiveness of medicines used in Parkinson's disease and restless legs syndrome (e.g., levodopa).
• This medicine may cause abnormalities in the electrocardiogram (ECG), manifested by prolongation of the electrical impulse through a specific part of the heart (known as "QT interval prolongation"). Other medicines with this effect include, among others, medicines used to regulate heart rhythm or treat infections, as well as other antipsychotic medicines.
• If the patient is prone to seizures, this medicine may increase the risk of their occurrence. Other medicines with this effect include, among others, some medicines used to treat depression or infections, as well as other antipsychotic medicines.
• Caution is advised when using Pratyria together with medicines that increase central nervous system activity (psychostimulants such as methylphenidate). Using Pratyria with alcohol Alcohol consumption should be avoided.

Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult her doctor or pharmacist before using this medicine.
Pregnancy
This medicine should not be used during pregnancy unless discussed with a doctor.
Newborns whose mothers took paliperidone during the third trimester (last 3 months of pregnancy) may experience the following symptoms: tremors, muscle stiffness and (or) weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If such symptoms are observed in the child, contact a doctor.
Breastfeeding
This medicine may pass from the mother's body into breast milk and harm the child. Therefore, breastfeeding should not be performed while using this medicine.
Driving and operating machinery
Dizziness, extreme tiredness, and vision disturbances may occur during treatment with this medicine (see section 4). This should be taken into account in situations requiring full alertness, such as driving a vehicle or operating machinery.
Pratyria contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, meaning the medicine is considered "sodium-free".

3. How to use Pratyria

The medicine will be administered by a doctor or other medical personnel. Your doctor will inform you when the next injection is due. It is important not to miss a scheduled dose. If you are unable to keep the scheduled appointment, you should immediately inform your doctor so that a new appointment can be arranged as soon as possible.

Dosage and method of administration

The first (150 mg) and second (100 mg) injections of this medicine will be given into the upper arm, approximately one week apart. Subsequently, an injection (in a dose ranging from 25 mg to 150 mg) will be administered into the upper arm or buttock once a month.

If your doctor decides to switch you from long-acting risperidone injections to this medicine, the first injection (in a dose ranging from 25 mg to 150 mg) will be given into the upper arm or buttock on the day your next scheduled injection is due. After that, an injection (in a dose ranging from 25 mg to 150 mg) will be administered into the upper arm or buttock once a month.

Depending on the symptoms present, your doctor may increase or decrease the dose by one level during the scheduled monthly injection.

Patients with kidney function impairment

Your doctor will adjust the dose based on kidney function. If you have mild kidney impairment, your doctor may reduce the dose. This medicine should not be used in cases of moderate or severe kidney impairment.

Elderly patients

Your doctor may reduce the dose if you have impaired kidney function.

Overdose of Pratyria

This medicine will be administered under medical supervision, so an overdose is unlikely.

In patients who have received an excessive dose of paliperidone, the following symptoms may occur: drowsiness and sedation, increased heart rate, low blood pressure, abnormal ECG (electrocardiogram) findings, or slowed or abnormal movements of the facial muscles, body, arms, or legs.

Stopping treatment with Pratyria

If you stop receiving the injections, the medicine will no longer work. Do not discontinue treatment unless instructed by your doctor, as symptoms of the illness may return.

If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
You should immediately inform your doctor if:

• the patient develops blood clots in the veins, especially in the legs (symptoms include swelling, pain and redness of the leg), which may travel through blood vessels to the lungs, causing chest pain and difficulty breathing. If such symptoms occur, seek immediate medical help.
• the patient with dementia experiences a sudden change in mental state or sudden weakness or numbness of the face, arms or legs, particularly on one side, or speech disturbances, even if brief. These symptoms may indicate a stroke.
• fever, muscle stiffness, sweating or decreased level of consciousness occurs (a condition called neuroleptic malignant syndrome). Immediate treatment may be required.
• a man experiences prolonged or painful erection. This condition is known as priapism. Immediate treatment may be necessary.
• involuntary rhythmic movements of the tongue, lips or face occur. Discontinuation of paliperidone treatment may be necessary.
• a severe allergic reaction occurs, characterised by: fever, swelling of the lips, face, tongue or throat, shortness of breath, itching, skin rash, and sometimes low blood pressure (known as "anaphylactic reaction"). Even if the patient previously tolerated oral risperidone or paliperidone, allergic reactions may rarely occur after paliperidone injections.
• the patient has planned eye surgery, the ophthalmologist should be informed about taking this medicine. During cataract removal, floppy iris syndrome may occur, which may lead to eye damage.
• the patient has a dangerously low number of certain white blood cells essential for fighting infections. The following adverse reactions may occur:

Very common adverse reactions: may occur in more than 1 in 10 patients

• difficulty falling asleep or waking up

Common adverse reactions: may occur in less than 1 in 10 patients

• cold-like symptoms, urinary tract infection, flu-like symptoms
• the medicine Pratyria may increase blood levels of the hormone prolactin (which may, but does not necessarily, cause symptoms). If symptoms of increased prolactin occur, they may include (in men): breast swelling, difficulty achieving or maintaining erection, or other sexual disturbances. In women, they may include breast discomfort, milk discharge from the breasts, absence of menstrual bleeding, or other menstrual cycle disturbances
• high blood sugar, weight gain, weight loss, decreased appetite
• irritability, depression, anxiety
• parkinsonism: this condition may include slow or abnormal movements, feelings of stiffness or muscle tension (causing uneven movements), and sometimes even a sensation of "freezing" of movements, followed by sudden release. Other symptoms of parkinsonism include: slow shuffling gait, resting tremor, increased salivation and (or) drooling and expressionless face
• psychomotor restlessness, feeling of drowsiness or reduced alertness
• dystonia: this condition involves slow or sustained involuntary muscle contractions. Although it may affect any part of the body (which may result in abnormal body posture), dystonia most commonly affects facial muscles, including abnormal eye, mouth, tongue or jaw movements
• dizziness
• dyskinesia: this condition involves involuntary muscle movements and may present as repetitive, spasmodic or twisting movements or jerks
• tremor
• headache
• rapid heartbeat
• high blood pressure
• cough, nasal congestion
• abdominal pain, vomiting, nausea, constipation, diarrhoea, indigestion, toothache
• increased liver enzyme activity in blood
• bone or muscle pain, back pain, joint pain
• absence of menstruation
• fever, weakness, fatigue
• injection site reaction, including itching, pain or swelling

Uncommon adverse reactions: may occur in less than 1 in 100 patients

• pneumonia, bronchitis, respiratory tract infections, sinus infection, bladder infection, ear infection, fungal nail infection, tonsillitis, skin infection
• decreased number of white blood cells, decreased number of certain white blood cells protecting against infections, anaemia
• allergic reaction
• onset of diabetes and worsening of pre-existing diabetes, increased blood insulin levels (hormone regulating blood sugar levels)
• increased appetite
• loss of appetite leading to malnutrition and low body weight
• high blood triglyceride levels (fats), increased blood cholesterol levels
• sleep disturbances, elevated mood (mania), decreased libido, nervousness, nightmares
• tardive dyskinesia (involuntary twitching or jerking movements of the face, tongue or other body parts). Inform your doctor immediately if involuntary rhythmic movements of the tongue, lips or face occur. Discontinuation of this medicine may be necessary
• fainting, need to move body parts, dizziness upon standing up, difficulty concentrating, speech difficulties, loss or altered sense of taste, reduced sensitivity to pain and touch on the skin, tingling, pricking or numbness of the skin
• blurred vision, eye infection or conjunctivitis, dry eyes
• dizziness, ringing in the ears, ear pain
• heart conduction block, abnormal electrical conduction in the heart, QT interval prolongation on ECG, rapid heartbeat upon standing, slow heart rate, abnormal ECG recording, palpitations (awareness of heart beating)
• low blood pressure, low blood pressure upon standing (as a result, some patients taking this medicine may faint, feel dizzy or lose consciousness when standing up suddenly)
• shortness of breath, sore throat, nosebleed
• abdominal discomfort, stomach or intestinal infection, difficulty swallowing, dry mouth
• excessive passing of gas
• increased GGTP enzyme activity (liver enzyme - gamma-glutamyl transferase) in blood, increased liver enzyme activity in blood
• hives, itching, rash, hair loss, skin rash, dry skin, redness of the skin, acne, subcutaneous abscess
• increased CPK (creatine phosphokinase) enzyme activity in blood, an enzyme sometimes released from damaged muscles
• muscle cramps, joint stiffness, muscle weakness
• urinary incontinence (uncontrolled), frequent urination, painful urination
• erectile dysfunction, ejaculation disorders, absence of menstruation and other menstrual cycle disturbances (women), breast enlargement in men, sexual disturbances, breast pain, milk discharge from the breasts
• swelling of the face, lips, eyes or mouth, body swelling, swelling of upper or lower limbs
• increased body temperature
• change in walking pattern
• chest pain, chest discomfort, malaise
• skin induration
• fall

Rare adverse reactions: may occur in less than 1 in 1,000 patients

• eye infection
• skin inflammation caused by mites, scaly, itchy skin of the head or other body parts
• increased number of eosinophils (a type of white blood cell) in blood
• decreased number of platelets (blood cells that help stop bleeding)
• head tremor
• abnormal secretion of the hormone regulating urine output
• glucose in urine
• life-threatening complications of untreated diabetes
• low blood sugar
• excessive water drinking
• lack of movement and response to stimuli in a patient who is not asleep (catatonia)
• confusion
• sleepwalking (somnambulism)
• lack of emotions
• inability to achieve orgasm
• neuroleptic malignant syndrome (confusion, decreased or loss of consciousness, high fever and severe muscle rigidity), cerebrovascular disorders including sudden interruption of blood flow to the brain (stroke or "mini" stroke), lack of response to stimuli, loss of consciousness, low level of consciousness, seizures, balance disturbances
• abnormal motor coordination
• glaucoma (increased pressure in the eyeball)
• eye movement disorders, rotational eye movements, light sensitivity, excessive tearing, redness of the eyes
• atrial fibrillation (irregular heartbeat), irregular heart rhythm
• blood clot in the lungs causing chest pain and breathing difficulties. If any of these symptoms occur, contact your doctor immediately
• blood clots in veins, especially in the lower limbs (symptoms include swelling, pain and redness of the lower limbs). If such symptoms occur, contact your doctor immediately
• episodes of flushing
• breathing disturbances during sleep (sleep apnoea)
• pulmonary congestion, respiratory tract hyperaemia
• crackling sounds in the lungs, wheezing
• pancreatitis, tongue swelling, faecal incontinence, very hard stool
• intestinal obstruction
• chapped lips
• drug-related skin rash, skin thickening, psoriasis
• muscle fibre breakdown and muscle pain (rhabdomyolysis)
• joint swelling
• inability to pass urine
• breast discomfort, enlargement of mammary glands, breast enlargement
• vaginal discharge
• priapism (prolonged erection, which may require surgical intervention)
• very low body temperature, chills, feeling of thirst
• withdrawal symptoms
• pus accumulation due to infection at the injection site, deep skin infection, abscess at the injection site, bruising at the injection site

Adverse reactions with unknown frequency: frequency cannot be determined from available data

• dangerously low number of certain white blood cells responsible for fighting infections
• severe allergic reaction characterised by fever, swelling of lips, face, tongue or throat, shallow breathing, itching, skin rash, and sometimes low blood pressure
• dangerously excessive water drinking
• eating disorders related to sleep
• coma due to uncontrolled diabetes
• reduced oxygenation of various body parts (due to reduced blood flow)
• rapid, shallow breathing, pneumonia caused by food aspiration, voice disturbances
• absence of intestinal peristalsis leading to obstruction
• yellowing of the skin and eyes (jaundice)
• severe or life-threatening blistering rash with skin peeling, which may appear in the mouth, nose, eyes, genital areas and around these areas, and may also spread to other body parts (Stevens-Johnson syndrome or toxic epidermal necrolysis)
• severe allergic reaction with swelling, which may involve the larynx and lead to breathing difficulties
• skin depigmentation
• abnormal body posture
• in newborns whose mothers used Pratyria during pregnancy, adverse reactions to the medicine and (or) withdrawal symptoms may occur, such as: irritability, slow or sustained muscle contractions, tremor, drowsiness, breathing difficulties and feeding problems
• low body temperature
• necrosis at the injection site and ulcer at the injection site

Reporting of adverse reactions
If any adverse reactions occur, including any adverse reactions not listed in this leaflet, inform your doctor, pharmacist or nurse. Adverse reactions can be reported directly to the Department of Monitoring of Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C
02-222 Warsaw
Tel.: +48 22 4921301
Fax: +48 22 4921309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.
By reporting adverse reactions, additional information on the safety of the medicine can be collected.

5. How to store the medicine Pratyria

Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the cardboard box and
carpule-syringe. The expiry date (EXP) refers to the last day of the stated month.
No special storage instructions are required for this medicine.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer in use. Such measures will help protect the environment.

6. Contents of the package and other information

What Pratyria contains
The active substance is paliperidone.
Each pre-filled syringe of Pratyria 75 mg contains paliperidone palmitate equivalent to 75 mg of paliperidone.
Each pre-filled syringe of Pratyria 100 mg contains paliperidone palmitate equivalent to 100 mg of paliperidone.
Each pre-filled syringe of Pratyria 150 mg contains paliperidone palmitate equivalent to 150 mg of paliperidone.
The other ingredients are:
Polysorbate 20 (E 432)
Macrogol 4000
Citric acid monohydrate (E330)
Disodium hydrogen phosphate anhydrous (E 339)
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide (E 542) (for pH adjustment)
Water for injections

What Pratyria looks like and contents of the pack
Pratyria is a white to off-white injectable suspension for prolonged release, supplied in a pre-filled syringe.
The pre-filled syringe is made of cyclo-olefin copolymer, with a bromobutyl rubber stopper (plunger tip), a safety lock, and a "tip-cap" needle attachment.
Each single pack contains: 1 pre-filled syringe and 2 needles.
Each initiation pack contains:

• 1 pack of Pratyria 150 mg, 1 pre-filled syringe and 2 needles (administered on day 1 of treatment)
• 1 pack of Pratyria 100 mg, 1 pre-filled syringe and 2 needles (administered on day 8 of treatment)

Not all pack sizes may be marketed.

Marketing Authorisation Holder
STADA Arzneimittel AG,
Stadastrasse 2-18,
61118 Bad Vilbel,
Germany

Manufacturer/Importer
STADA Arzneimittel AG,
Stadastrasse 2-18,
61118 Bad Vilbel,
Germany
Stada Arzneimittel GmbH
Muthgasse 36/2, Doebling
1190 Vienna,
Austria

For further information regarding this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
STADA Pharm Sp. z o.o.
ul. Krakowiaków 44
02-255 Warsaw
Tel. +48 22 737 79 20

Packaging with Magellan safety needle

Information intended exclusively for medical or healthcare personnel and must be read together with the full product information (Summary of Product Characteristics).

The injectable suspension is for single use only. Before administration, inspect visually for foreign particles. If foreign particles are visible in the prefilled syringe, do not use the medicinal product.

The package contains one prefilled syringe and two safety needles (22G x 1½ inches [38 mm x 0,7 mm] and 23G x 1 inch [25 mm x 0,6 mm]) for intramuscular administration.

1. Shake the prefilled syringe vigorously for at least 10 seconds to ensure homogeneity of the suspension.

2. Select the appropriate needle.

The first initiating dose of the medicinal product Pratyria (150 mg) should be administered on day 1 of treatment into the DELTOID MUSCLE, using the DELTOID MUSCLE needle. The second initiating dose of the medicinal product Pratyria (100 mg) should be administered one week later (day 8), also into the DELTOID MUSCLE, using the DELTOID MUSCLE needle.

If switching from long-acting risperidone injections to the medicinal product Pratyria, the first injection of Pratyria (at a dose ranging from 25 mg to 150 mg) may be administered into either the DELTOID MUSCLE or GLUTEAL MUSCLE, using the appropriate needle, on the day of the next scheduled injection.

Subsequently, monthly maintenance doses may be administered into either the DELTOID MUSCLE or GLUTEAL MUSCLE, using the appropriate needle.

For intramuscular injections into the DELTOID MUSCLE in patients with body weight <90 kg, use a 1-inch, 23G (25 mm x 0.6 mm) needle (blue hub). If the patient's body weight is ≥90 kg, use a 1½-inch, 22G (38 mm x 0.7 mm) needle (gray hub).

For intramuscular injections into the GLUTEAL MUSCLE, use a 1½-inch, 22G (38 mm x 0.7 mm) needle (gray hub).

3. Hold the syringe with the tip pointing upward. Remove the rubber cap with a gentle twisting motion.

4. Partially peel back the outer part of the blister packaging of the safety needle. Grasp the needle shield through the plastic packaging. Hold the syringe upright. Attach the safety needle to the syringe by gently screwing it on to avoid breakage or damage to the needle tip. Before administration, always check for signs of damage or leakage.

5. Remove the needle shield with a straight pull. Do not twist the shield, as this may loosen the needle from the prefilled syringe.

6. Expel air from the prefilled syringe by gently pressing the plunger while holding the syringe in an upright position.

7. Inject the entire content of the prefilled syringe intramuscularly, slowly and deeply, into the selected muscle of the patient — either deltoid or gluteal. Do not administer the medicinal product intravenously or subcutaneously.

8. After completing the injection, activate the needle safety mechanism by pressing the needle shield with the thumb or finger of one hand (8a, 8b) or against a flat surface (8c). A clicking sound indicates successful activation of the needle safety. Dispose of the prefilled syringe with the attached needle properly.

Any unused portions of the product or waste materials should be disposed of in accordance with local regulations.

Packaging with Terumo safety needle

Information intended exclusively for medical or healthcare personnel

and must be read together with the full product information (Summary of Product Characteristics).
The injection suspension is intended for single use only. Before administration, inspect visually for foreign particles. If foreign particles are observed in the prefilled syringe, do not use the medicinal product.
The package contains one prefilled syringe and two safety needles (22G x 1½ inches [38 mm x 0.7 mm] and 23G x 1 inch [25 mm x 0.6 mm]) for intramuscular administration.

1. Shake the prefilled syringe vigorously for at least 10 seconds to ensure homogeneity of the suspension.

2. Select the appropriate needle.

For injections into the DELTOID MUSCLE:

• For patients with body weight <90 kg, use a 1-inch, 23G needle (needle with blue hub).
• For patients with body weight ≥90 kg, use a 1½-inch, 22G needle (needle with gray hub).

For injections into the GLUTEAL MUSCLE:
Use a 1½-inch, 22G needle (needle with gray hub) regardless of patient body weight.

3. Hold the syringe with the tip pointing upward and remove the rubber cap with a gentle twisting motion.

4. Partially peel back the outer part of the safety needle packaging. Hold the needle sheath through the packaging. Attach the safety needle to the syringe and gently screw it on clockwise.

5. 1. Slide the needle shield toward the syringe. 2) Remove the needle sheath with a straight pull. Do not rotate the sheath, as this may loosen the needle from the prefilled sy游戏副本.

6. Remove air from the prefilled syringe by gently pressing the plunger while holding the syringe in an upright position.

7. Inject the entire contents of the prefilled syringe intramuscularly, slowly and deeply, into the selected muscle of the patient — either deltoid or gluteal. Do not administer the medicinal product intravenously or subcutaneously.
8. After injection, secure the needle by using the thumb or finger of one hand (8a, 8b) or a flat surface (8c). A clicking sound indicates successful needle protection. Dispose of the prefilled syringe with the needle properly.

Keep out of reach of children.
Any unused product or waste material should be disposed of in accordance with local regulations.